Depressive symptoms are associated with oxidative stress in middle-aged women: a cross-sectional study

Asuka Hirose, Masakazu Terauchi, Mihoko Akiyoshi, Yoko Owa, Kiyoko Kato and Toshiro Kubota

Abstract

Background: Oxidative stress is known to be a factor in various diseases. In this study, we investigated whether physical and psychological symptoms of menopause, cardiovascular parameters, body composition, and lifestyle factors are associated with oxidative stress in middle-aged women.

Methods: This cross-sectional study used baseline data collected in a previous study that examined the effects of a dietary supplement on a variety of health parameters in 95 women aged 40 to 60 years. Participants had been assessed for age, menopausal status, body composition, cardiovascular parameters, physical and psychological symptoms of menopause, and lifestyle factors. Urinary 8-hydroxy-2′-deoxyguanosine (8-OHdG) level, an oxidative stress marker, had also been measured. Dichotomizing 8-OHdG levels as low (≤25 ng/mg creatinine) and high (>25 ng/mg creatinine), we sought to identify the health parameters that are associated with high 8-OHdG level.

Results: Women with a high 8-OHdG level had lower body weight, lower body mass index, lower body fat mass, higher body temperature, scored higher for both anxiety and depression on the Hospital Anxiety and Depression Scale (HADS), and consumed more alcohol. Multiple logistic regression analysis revealed that the HADS-depression subscale (HADS-D) score was the sole independent contributor to high 8-OHdG level (adjusted odds ratio, 1.23 per point increase in HADS-D score; 95% confidence interval, 1.06–1.45).

Conclusion: Depressive symptom score was shown to be independently associated with high 8-OHdG level in middle-aged women, suggesting a link between mood disorder and oxidative stress.

Trial registration: UMIN-CTR UMIN000009353.

Keywords: 8-OHdG, Mood disorder, Menopausal symptoms, Depression, Menopause
myocardial infarction [13], Parkinson’s disease [14], Alzheimer’s disease [15], inflammatory airway diseases [16], and age-related illness [17]. The severity of oxidative stress can be quantified by measuring the concentration of specific biomarkers, one of which is 8-hydroxy-2′-deoxyguanosine (8-OHdG), an index of oxidatively damaged DNA [18, 19]. Recently, a novel automatic analyzer for competitive immunochromatography was developed, making measurement of urinary 8-OHdG level much quicker and easier than before.

The aim of this study was to investigate whether physical and psychological symptoms of menopause, cardiovascular parameters, body composition, and lifestyle factors are associated with oxidative stress in middle-aged women using urinary 8-OHdG level as a marker.

Methods
Study population
We performed a cross-sectional analysis using the baseline data of a previous study [20] conducted at the Menopause Clinic of Tokyo Medical and Dental University to examine the effects of a dietary supplement on a variety of health parameters in 95 Japanese women aged 40 to 60 years. The participants were recruited through advertisements posted in our hospital and the patients’ own social network. Women who scored positive for at least one symptom item on the Menopausal Health-Related Quality of Life (MHR-QOL) Questionnaire were eligible for the study, and those who were receiving menopausal hormone therapy were excluded. Collected data included age, menopausal status, lifestyle factors, physical and psychological symptoms of menopause, body composition, cardiovascular parameters, and urinary 8-OHdG level. The study protocol was reviewed and approved by the Medical Research Ethics Committee of Tokyo Medical and Dental University (No. 1359), and written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki.

Regarding menopausal status, participants were classified as follows: premenopausal (regular menstrual cycles in the past 3 months), perimenopausal (a menstrual period within the past 12 months but a missed period or irregular cycles in the past 3 months), postmenopausal (no menstrual period in the past 12 months), or surgically induced menopause (hysterectomy).

Body composition and cardiovascular parameters
Body composition, including height, weight, body mass index, fat mass, and muscle mass, was assessed using a body composition analyzer (MC190-EM; Tanita, Tokyo, Japan). Cardiovascular parameters, including systolic and diastolic blood pressure, heart rate, and arterial stiffness index (cardio-ankle vascular index), were measured using a vascular screening system (VS-1000; Fukuda Denshi Co., Tokyo, Japan).

Menopausal symptoms
Menopausal symptoms were evaluated using the MHR-QOL Questionnaire, Hospital Anxiety and Depression Scale (HADS), and Athens Insomnia Scale (AIS). The MHR-QOL Questionnaire, developed and validated in our clinic, is a modification of the Women’s Health Questionnaire [21, 22] that contains 38 items scored on a four-point or binary scale covering four major domains (physical health, mental health, life satisfaction, and social involvement) of a woman’s health during menopause. The physical health domain consists of nine items that assess somatic (sickness/nausea, dizzy spells, tingling/numbness, backache/pain in limbs, tiredness, and headaches), urinary (urinary frequency), and vasomotor (hot flashes and night sweats) symptoms. The mental health domain consists of 12 items that assess symptoms of loss of interest in things, lack of enjoyment, low energy, depressed mood, poor memory, difficulty in concentration, frightened/panicky feelings, feeling tense/wound up, dissatisfaction with sexual relationship, difficulty in initiating sleep, nonrestorative sleep, and low self-esteem. Higher scores on the items indicate worse physical function (0 points, none to once per month; 1 point, 1–2 times per week; 2 points, 3–4 times per week; 3 points, almost every day). The total scores of the physical and mental health domains were designated the “physical symptom score” and “psychological symptom score” respectively. The HADS, developed by Zigmond and Snaith [23], is a reliable instrument for screening clinically significant anxiety and depressive symptoms in women visiting a general medicine clinic; it has been translated into Japanese by Kitamura et al. [24]. The AIS was developed as a brief and easy-to-administer self-assessment questionnaire for determining the severity of insomnia defined according to the International Classification of Diseases 10th Revision. The internal consistency and test-retest reliability of the AIS have been confirmed previously [25]. Detailed information about the MHR-QOL Questionnaire, HADS, and AIS is provided elsewhere [20].

Oxidative stress
Urinary 8-OHdG level was measured by competitive immunochromatography using a novel automatic analyzer (ICR-001; Techno Medica, Tokyo, Japan). The participants produced urine samples at our clinic, which were instantly centrifuged at 3000 rpm for 5 min. After dilution twice with distilled water, 8-OHdG (ng) and creatinine (mg) concentration were measured to calculate 8-OHdG level corrected by creatinine (ng/mg creatinine). In the present study, we dichotomized 8-OHdG levels as low (≤25 ng/mg creatinine) and high (>25 ng/mg creatinine) according
to previous research that analyzed 140 samples collected from healthy workers at a coke oven plant [26]. In that study, the mean ± SD value measured by using enzyme-linked immunosorbent assay (ELISA) was 14.9 ± 9.3 ng/mg creatinine in subjects who were employed in the coke operation area and 14.7 ± 12.8 ng/mg creatinine in subjects who worked only in an administrative area. Based on the mean ± 1SD value in that study, we arbitrarily set our cut-off index at 25 ng/mg creatinine.

### Statistical analyses

First, all variables were compared between the two 8-OHdG level groups using univariate analysis (unpaired t test, chi-square test, and Mann–Whitney U test). Then, variables emerging with possible prognostic value for high 8-OHdG level (P < 0.20) were entered into stepwise multiple logistic regression analysis. Variables that remained significant (P < 0.05) were retained in the final multivariable model and were considered to be associated with oxidative stress in middle-aged women. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).

### Results

The 95 participants were divided into two groups according to urinary 8-OHdG level: 59 women had a low level (<25 ng/mg creatinine) and 36 had a high level (>25 ng/mg creatinine).

The background characteristics of the women are shown by group in Table 1. First, we examined differences between groups using univariate analysis to select variables with possible prognostic value for high 8-OHdG level. Mean age and menopausal status were similar between groups. Women with a high 8-OHdG level tended to have lower body weight (51.0 ± 8.3 kg vs. 53.5 ± 6.5 kg, P = 0.111), lower body mass index (20.6 ± 3.4 kg/m² vs. 21.9 ± 2.5 kg/m², P = 0.048), lower body fat mass (12.9 ± 6.3 kg vs. 15.1 ± 4.8 kg, P = 0.062), higher body temperature (36.4 ± 0.4 °C vs. 36.2 ± 0.5 °C, P = 0.123), scored higher for anxiety (6.0 ± 3.4 vs. 4.9 ± 2.6, P = 0.100) and depression (5.3 ± 3.6 vs. 3.5 ± 2.3, P = 0.018) on the HADS, and scored higher on the MHR-QOL psychological symptom score (8.2 ± 8.9 vs. 4.6 ± 4.7, P = 0.054). They also consumed more alcohol (proportion of women who drank daily, 22.2% vs. 11.9%, P = 0.196) (Table 1).

Next, these variables were entered into multivariate analysis to identify the factors that contribute independently to high 8-OHdG level, except for MHR-QOL psychological symptom scores, as they were represented by HADS-anxiety and depression scores. Stepwise multiple logistic regression analysis revealed that, among these factors, HADS-depression subscale (HADS-D) score was the sole independent contributor to high 8-OHdG level (adjusted odds ratio, 1.23 per point increase in HADS-D score; 95% confidence interval, 1.06–1.45) (Table 2). Considering the multicollinearity of the three body composition variables, we analyzed the data putting each of them into multiple logistic regression analysis, only to find HADS-depression score was still the sole independent contributor to high 8-OHdG level (data not shown).

### Table 1 Background characteristics of the participants

| Age, y | Menopausal status,% | Premenopausal | Perimenopausal | Postmenopausal | Surgically induced menopause | Body composition | Cardiovascular parameters |
|--------|---------------------|---------------|---------------|---------------|-----------------------------|-----------------|--------------------------|
|        | Low 8-OHdG level (n = 59) | High 8-OHdG level (n = 36) | P value |
|        | Age, y | 49.5 ± 5.1 | 50.0 ± 5.0 | 0.637<sup>a</sup> |
| Menopausal status,% | Premenopausal | 42.4 | 38.9 | 0.771<sup>b</sup> |
|        | Perimenopausal | 22.0 | 22.2 | 0.865<sup>c</sup> |
|        | Postmenopausal | 25.4 | 33.3 | 0.760<sup>d</sup> |
|        | Surgically induced menopause | 10.2 | 5.6 | 1.000<sup>e</sup> |
|        | Body composition |  |  |  |
|        | Height, cm | 156.4 ± 5.3 | 157.2 ± 4.6 | 0.434<sup>a</sup> |
|        | Weight, kg | 53.5 ± 6.5 | 51.0 ± 8.3 | 0.111<sup>a</sup> |
|        | Body mass index, kg/cm² | 21.9 ± 2.5 | 20.6 ± 3.4 | 0.048<sup>a</sup> |
|        | Body fat mass, kg | 15.1 ± 4.8 | 12.9 ± 6.3 | 0.062<sup>a</sup> |
|        | Muscle mass, kg | 36.2 ± 2.5 | 35.9 ± 2.7 | 0.630<sup>d</sup> |
|        | Waisthip ratio, % | 85.6 ± 6.9 | 85.1 ± 8.4 | 0.760<sup>d</sup> |
|        | Body temperature, °C | 36.2 ± 0.5 | 36.4 ± 0.4 | 0.123<sup>a</sup> |
|        | Cardiovascular parameters |  |  |  |
|        | Systolic blood pressure, mmHg | 122.5 ± 14.6 | 119.4 ± 15.5 | 0.317<sup>a</sup> |
|        | Diastolic blood pressure, mmHg | 78.6 ± 10.3 | 76.9 ± 10.3 | 0.433<sup>a</sup> |
|        | Heart rate, beats/min | 63.3 ± 7.5 | 64.9 ± 9.8 | 0.382<sup>a</sup> |
|        | CAVI | 7.16 ± 0.68 | 7.29 ± 0.83 | 0.405<sup>a</sup> |
|        | MHR-QOL physical symptom score | 5.58 ± 3.41 | 5.81 ± 3.85 | 0.865<sup>c</sup> |
|        | MHR-QOL psychological symptom score | 4.63 ± 4.71 | 8.17 ± 8.85 | 0.054<sup>c</sup> |
|        | HADS-anxiety subscale score | 4.86 ± 2.62 | 6.03 ± 3.36 | 0.100<sup>c</sup> |
|        | HADS-depression subscale score | 3.48 ± 2.30 | 5.25 ± 3.63 | 0.018<sup>c</sup> |
|        | AIS score | 4.09 ± 2.99 | 3.75 ± 3.11 | 0.524<sup>c</sup> |
|        | Lifestyle factors,% |  |  |  |
|        | Working | 89.8 | 83.3 | 0.362<sup>c</sup> |
|        | Exercising regularly | 45.8 | 47.2 | 1.000<sup>c</sup> |
|        | Smoking | 8.5 | 16.7 | 0.322<sup>c</sup> |
|        | Drinking alcohol (daily/by chance/not at all) | 11.9/57.6/70.5 | 22.2/61.1/16.7 | 0.196<sup>c</sup> |

Values are presented as mean ± SD unless otherwise indicated. AIS Athens insomnia scale, CAVI cardio-ankle vascular index, HADS hospital anxiety and depression scale, MHR-QOL menopausal health-related quality of life.

<sup>a</sup> According to the unpaired t test, <sup>b</sup> According to the Mann–Whitney U test, <sup>c</sup> According to the chi-square test, <sup>d</sup> According to the unpaired t test.


**Table 2** Factors associated with high urinary 8-OHdG level (>25 ng/mg creatinine) according to multiple logistic regression analysis

| Factor                        | Crude OR (95 % CI) | P value | Adjusted OR (95 % CI) | P value |
|-------------------------------|--------------------|---------|-----------------------|---------|
| Weight                        | 0.95 (0.89–1.01)   | 0.110   |                       |         |
| Body mass index               | 0.84 (0.70–0.98)   | 0.038   |                       |         |
| Body fat mass                 | 0.92 (0.84–1.00)   | 0.056   |                       |         |
| Body temperature              | 2.16 (0.84–6.13)   | 0.126   |                       |         |
| HADS-anxiety subscale score   | 1.14 (0.99–1.32)   | 0.083   |                       |         |
| HADS-depression subscale score| 1.23 (1.06–1.45)   | 0.011   | 1.23 (1.06–1.45)      | 0.011   |
| Daily alcohol consumption     | 2.20 (0.72–6.72)   | 0.166   |                       |         |

CI confidence interval, HADS hospital anxiety and depression scale, OR odds ratio

**Discussion**

In this cross-sectional analysis of 95 middle-aged women, we investigated the associations between various health parameters and oxidative stress and revealed that the depressive symptom score was independently associated with high urinary 8-OHdG level, suggesting a link between mood disorder and oxidative stress. The result that all the variables except depressive symptom score did not remain in the final model suggests that their association with oxidative stress was cofounded with depressive symptoms.

In order to evaluate the state of oxidative stress, various biomarkers have been developed to assess the damage induced by ROS or the defense provided by antioxidants. Well-known biomarkers include malondialdehyde, hexanoyl-lysine, isoprostanes, and protein carbonyls, which are produced through oxidative damage of lipids and proteins, while antioxidant enzymes include superoxide dismutase, catalase, glutathione peroxidase, and glutathione [8, 27].

8-OHdG, deoxyguanosine hydroxylated at the C-8 position, is a biomarker of oxidative DNA damage [18, 19]. First reported by Kasai et al. in 1984 [28], it has become one of the most widely used markers of oxidative stress. Chemical carcinogens, tumor-promoting agents, and lifestyle factors, such as smoking and drinking, have been reported to increase 8-OHdG level in human organ and leukocyte DNA [18, 19, 29]. Urinary 8-OHdG level can be measured by cumbersome methods, such as high-performance liquid chromatography with electrochemical detection, gas chromatography with mass spectrometry, liquid chromatography with tandem mass spectrometry, and ELISA [30]. A recently developed automatic analyzer for competitive immunochromatography, ICR-001, has made measurement of urinary 8-OHdG level much quicker and easier than before. Thus far, three research papers have been published using the ICR-001 system to measure urinary 8-OHdG levels [31–33].

For middle-aged women, depression is an important health care issue. Although, the main predictor of depression during the perimenopausal period is the symptom before menopause in addition to other psychosocial factors, several studies have suggested that new-onset depressive symptoms increase during the transition to menopause [34]. One study also revealed that fluctuations rather than absolute levels in estradiol and follicle-stimulating hormone in postmenopausal women are associated with increased risk of depressive symptoms [35]. A meta-analysis of 23 studies was recently performed to evaluate the association between depression and oxidative stress and/or antioxidant status in general [36]. Depressive symptoms were found to be associated with increased oxidative stress and lower antioxidant status; however, the measures of oxidative stress and antioxidant status, the assessment of depressive symptoms, and the sample populations were heterogeneous. Some studies using peripheral leukocytes [37], sera [6, 38, 39] or urine samples [40, 41] have revealed an association between depressive symptoms and high 8-OHdG level. Regarding the two studies using urine samples, one investigated the association between 8-OHdG level with major depression and myalgic encephalomyelitis/chronic fatigue syndrome [40], while the other assessed the urinary excretion of the oxidative stress marker throughout the menstrual cycle in young women [41]. The present study was the first to use a novel automatic analyzer of urinary 8-OHdG level to investigate the association between depressive symptoms and oxidative stress in middle-aged women.

Although the mechanisms linking depressive symptoms to oxidative stress remain unknown, some possibilities are suggested. First, depressed women may have lifestyles or behaviors that increase oxidative stress. Second, depressive symptoms may lead to increased production of ROS, which would contribute to oxidative stress. Third, depressive symptoms may weaken the antioxidant defense system. Fourth, the fluctuations in estradiol and follicle-stimulating hormone, which are suggested to be associated with depressive symptoms [35], may also increase oxidative stress. Finally, high oxidative stress may lower serotonin and norepinephrine levels, which would lead to depressive symptoms. In the present study, we negated the possibility that other factors such as age, menopausal status, lifestyle factors (including working, exercise, smoking, and alcohol consumption), physical and psychological symptoms of
menopause, body composition, and cardiovascular parameters were confounding. Depressive symptoms and oxidative stress may affect bidirectionally; thus, further research is required to clarify the underlying mechanisms that evaluates several oxidative stress biomarkers, including resultant oxidative products and antioxidant enzymes simultaneously, as well as estradiol, follicle-stimulating hormone, serotonin, and norepinephrine levels.

The present study has some limitations: (1) the number of participants was relatively small, and (2) all participants were relatively healthy women. In order to determine the association between oxidative stress and depressive symptoms, further studies with a larger sample including middle-aged women with more severe depressive symptoms are warranted.

Conclusion
Depressive symptom score was shown to be independently associated with high 8-OHdG level in middle-aged women, suggesting a link between mood disorder and oxidative stress in this population.

Ethics approval and consent to participate
The study protocol was reviewed and approved by the Medical Research Ethics Committee of Tokyo Medical and Dental University (No. 1359), and written informed consent was obtained from all participants. The study was conducted in accordance with the Declaration of Helsinki.

Consent for publication
Not applicable.

Availability of data and materials
The datasets are available upon reasonable request.

Abbreviations
AIS: Athens insomnia scale; CVD: cardiovascular disease; ELISA: enzyme-linked immunosorbent assay; HADS: hospital anxiety and depression scale; MHRQOL: menopausal health-related quality of life; ROS: reactive oxygen species; 8-OHdG: 8-hydroxy-2'-deoxyguanosine.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AH and MT conceptualized and designed the study and collected and analyzed the data. TK participated in the design of the study and the project supervision. MA, YO, and KK participated in the data collection. AH drafted the manuscript. All authors have read and approved the final manuscript.

Acknowledgements
This research was supported by Kikkoman Corporation.

Funding
MT received an unrestricted research grant from Kikkoman Corporation.

Author details
1Department of Obstetrics and Gynecology, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo, Tokyo 113-8510, Japan. 2Department of Women’s Health, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo, Tokyo 113-8510, Japan.

Received: 8 February 2016 Accepted: 18 April 2016
Published online: 26 April 2016

References
1. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88:2404–11.
2. Rosano GM, Vitale C, Tulli A. Managing cardiovascular risk in menopausal women. Climacteric. 2006;9(Suppl 1):19–27.
3. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, et al. Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiology and gynaecologists. Eur Heart J. 2007;28:2028–40.
4. Lizcano F, Guzman G. Estrogen Deficiency and the Origin of Obesity during Menopause. Biomed Res Int. 2014;2014:757461. doi:10.1155/2014/757461.
5. Kalyanaraman B. Teaching the basics of redox biology to medical and graduate students: Oxidants, antioxidants and disease mechanisms. Redox Biol. 2013;1:244–57.
6. Wei YC, Zhou FL, He DL, Bai JR, Hui LY, Wang XY, et al. The level of oxidative stress and the expression of genes involved in DNA-damage signaling pathways in depressive patients with colorectal carcinoma. J Psychosom Res. 2009;66:259–66.
7. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.
8. Poljak B, Suput D, Milisavljevic B. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013;2013:956792. doi:10.1155/2013/956792.
9. Higami Y, Shimokawa I. Aporphosis in the aging process. Cell Tissue Res. 2000;301:125–32.
10. Sies H, Cadenas E. Oxidative stress: damage to intact cells and organs. Philos Trans R Soc Lond B Biol Sci. 1985;311:617–31.
11. Hattersley B. Oxidative stress and cancer: have we moved forward? Biochem J. 2007;401:1–11.
12. Schleicher E, Friess U. Oxidative stress, AGE, and atherosclerosis. Kidney Int Suppl. 2007;106:S17–26.
13. Chen SR, Zweier JL. Cardiac mitochondria and reactive oxygen species generation. Circ Res. 2014;114:524–37.
14. Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson’s disease. J Parkinsonism. Dis. 2013;3:461–91.
15. Choi DY, Lee YJ, Hong JT, Lee HJ. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. J. Biol. Chem. 2010;285:12697–704.
16. Wood LG, Wark PA, Garg ML. Antioxidant and anti-inflammatory effects of resveratrol in airway disease. Antioxid Redox Signal. 2010;13:1535–48.
17. Yan LJ. Positive oxidative stress in aging and aging-related disease. Redox Biol. 2014;2C:165–9.
18. Kasai H. Analysis of a form of oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine, as a marker of cellular oxidative stress during carcinogenesis. Mutat Res. 1997;387:147–63.
19. Wu LL, Chiou CC, Chang PY, Wu JT. Uninary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetes. Clin Chim Acta. 2004;339:1–9.
20. Terauchi M, Horiguchi N, Kajiyama A, Akiyoshi M, Owa Y, Kato K, et al. Effects of grape seed proanthocyanidin extract on menopausal symptoms, body composition, and cardiovascular parameters in middle-aged women: a randomized, double-blind, placebo-controlled pilot study. Menopause. 2014;21:990–6.
21. Hunter M, Batterby R, Whitehead M. Relationships between psychological symptoms, somatic complaints and menopausal status. Maturitas. 1986;8:217–28.
22. Hunter M. The south-east England longitudinal study of the climacteric and postmenopause. Maturitas. 1992;14:117–26.
23. Zigmond AS, Snarth RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.
24. Zigmond AS, Snarth RP, Kitamura T. The Hospital Anxiety and Depression Scale (in Japanese). Seisinka-Sindangaku. 1993;4:1371–2.
25. Soldatos CR, Dikeos DG, Paparrigopoulos T.J. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res. 2000;48:555–60.
26. Hu CW, Wu MT, Chao MR, Pan CH, Wang CJ, Swenberg JA, et al. Comparison of analyses of urinary 8-hydroxy-2′-deoxyguanosine by isotope-dilution liquid chromatography with electrospray tandem mass spectrometry and by enzyme-linked immunosorbent assay. Rapid Commun Mass Spectrom. 2004;18:505–10.

27. Dalle-Donne I, Rossi R, Calombo R, Giustarini D, Miltani A. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601–23.

28. Kasai H, Hayami H, Yamaizumi Z, Saitô H, Nishimura S. Detection and identification of mutagens and carcinogens as their adducts with guanosine derivatives. Nucleic Acids Res. 1984;12:2127–36.

29. Mei S, Yao Q, Wu C, Xu G. Determination of urinary 8-hydroxy-2′-deoxyguanosine by two approaches-capillary electrophoresis and GC/MS: an assay for in vivo oxidative DNA damage in cancer patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827:83–7.

30. Pilger A, Rüdiger HW. 8-Hydroxy-2′-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures. Int Arch Occup Environ Health. 2006;80:1–15.

31. Masugata H, Senda S, Murao K, Inukai M, Himoto T, Hosomi N, et al. Association between urinary 8-hydroxydeoxyguanosine, an indicator of oxidative stress, and the cardio-ankle vascular index in hypertensive patients. J Atheroscler Thromb. 2012;19:747–55.

32. Masugata H, Senda S, Inukai M, Himoto T, Imachi H, Murao K, et al. Association between oxidative stress assessed by urinary 8-hydroxydeoxyguanosine and the cardiac function in hypertensive patients without overt heart disease. Clin Exp Hypertens. 2013;35:308–12.

33. Kaneko K, Kimata T, Tsuji S, Ohashi A, Imai Y, Sudo H, et al. Measurement of urinary 8-oxo-7,8-dihydro-2′-deoxyguanosine in a novel point-of-care testing device to assess oxidative stress in children. Clin Chim Acta. 2012;413:1822–6.

34. Llaneza P, García-Portilla MP, Llaneza-Suárez D, Armott B, Pérez-López FR. Depressive disorders and the menopause transition. Maturitas. 2012;71:120–30.

35. Ryan J, Burger HG, Szoeke C, Lehert P, Ancelin ML, Henderson VW, et al. A prospective study of the association between endogenous hormones and depressive symptoms in postmenopausal women. Menopause. 2009;16:509–17.

36. Palta P, Samuel LJ, Miller ER, Szanton SL. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosom Med. 2014;76:12–9.

37. Irie M, Miyata M, Kasai H. Depression and possible cancer risk due to oxidative DNA damage. J Psychiatr Res. 2005;39:533–60.

38. Forlenza MJ, Miller GE. Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression. Psychosom Med. 2006;68:1–7.

39. Kupper N, Gidron Y, Winter J, Denollet J. Association between type D personality, depression, and oxidative stress in patients with chronic heart failure. Psychosom Med. 2009;71:1973–80.

40. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E. Increased 8-hydroxydeoxyguanosine, a marker of oxidative damage to DNA, in major depression and myalgic encephalomyelitis/chronic fatigue syndrome. Neuro Endocrinol Lett. 2009;30:715–22.

41. Iida T, Inoue K, Ito Y, Ishikawa H, Kagiyama M, Terada R, et al. Comparison of urinary levels of 8-hydroxy-2′-deoxyguanosine between young females with and without depressive symptoms during different menstrual phases. Acta Med Okayama. 2015;69:45–50.